This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Decapeptyl (EU), Debio 8206 (IM), Trelstar Depot, Trelstar Long-Acting (LA), triptorelin embonate, Pamorelin, Salvacyl
Description: BioMedTracker has separate profiles for the subcutaneous and intramuscular formulations of triptorelin pamoate. Please also see Debio 8206.
Trelstar 3.75mg, Trelstar 11.25mg, and Trelstar 22.5mg (triptorelin pamoate for injectable suspension), a peptide formulation using Debiopharm S.A.'s Debio PLGA proprietary technology, are one-, three-, and six-month sustained-release formulations of triptorelin, an analog of luteinizing hormone-releasing hormone (LHRH or GnRH) with greater potency than naturally occurring LHRH.
The active substance of the drug is triptorelin, adecapeptide analogue of GnRH (Gonadotrophin Releasing Hormone), a hormone secreted by thehypothalamus, which initially stimulates the release of pituitary gonadotrophins (hormones produced by the pituitary gland), which in turn control hormonal secretions by the testes and ovaries.
In 1982, Debiopharm in-licensed Decapeptyl from Tulane University.
Watson and Debiopharm
In September 1994, Debiopharm announced that it entered into an exclusive license agreement in which Watson Pharmaceuticals acquired rights to market and sell Trelstar.
In January 2013, Watson changed its name to Actavis.
Debiopharm, Pharmacia and Pfizer
In December 2003, Debiopharm agreed to reacquire from Pfizer the sales and marketing rights to Trelstar Depot 3.75mg one month formulation, and Trelstar LA 11.25mg, the three month formulation, in the United States, Canada and Mexico. Debiopharm had previously licensed the rights to Trelstar to Pharmacia and Pfizer obtained these rights through its acquisition of Pharmacia in April 2003.
Paladin and Watson
In May 2005, Paladin Labs announced that it entered into a Canadian marketing and supply agreement with Watson Pharma to market Trelstar 3.75 mg and Trelstar LA 11.25...See full deal structure in Biomedtracker
Partners: Ipsen SA Debiopharm S.A. The Galenica Group Orient Europharma Co., Ltd. Arbor Pharmaceuticals, Inc.
Additional information available to subscribers only: